中信证券股份有限公司 关于思创医惠科技股份有限公司 2023年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：思创医惠 | | --- | --- | | 保荐代表人姓名：马齐玮 | 联系电话：0571-85783756 | | 保荐代表人姓名：徐峰 | 联系电话：0571-85783756 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | | 就公司是否有效执行相关规章制度事项，审计 | | | 机构在其2023年审计意见中表示："上述事项 | | | 反映思创医惠公司内部控制存在缺陷"。 | | | 就该事项，本保荐机构取得并查阅了审计机构 | | | 出具的2 ...

公司已于近日办理完成上述全资孙公司工商注册登记，并取得了苍南县市 场监督管理局颁发的《营业执照》，具体注册信息如下： 1、名称：思创物联（苍南）有限公司 | 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2024-069 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于投资设立全资孙公司的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 思创医惠科技股份有限公司（以下简称"公司"）于 2024 年 5 月 6 日召开 第五届董事会第四十一次会议，审议通过了《关于投资设立全资孙公司的议 案》。具体内容详见公司于 2024 年 5 月 7 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于投资设立全资孙公司的公告》 （公告编号：2024-067）。 二、对外投资进展情况 2、统一社会信用代码：91330327MADL85E49G 3、注册资本：叁仟万元整 4、类型：有限责任公司（自然人投资或控股的法人独资） ...

中信证券股份有限公司关于 思创医惠科技股份有限公司向不特定对象发行可转换公司债券 持续督导保荐总结报告书 保荐人编号：Z20374000 申报时间：2024 年 5 月 本次发行的可转债规模为 81,700.00 万元，每张面值为人民币 100 元，共计 8,170,000 张。本次向不特定对象发行的可转换公司债券向发行人在股权登记日 （2021 年 1 月 25 日，T-1 日）收市后中国证券登记结算有限责任公司深圳分公 1 司（以下简称"中国结算深圳分公司"）登记在册的原股东优先配售，原股东优 先配售后余额部分（含原股东放弃优先配售部分）通过深圳证券交易所（以下简 称"深交所"）交易系统向社会公众投资者发行。本次可转换公司债券发行总额 为 81,700.00 万元，向原股东优先配售 4,245,380 张，即 424,538,000.00 元，占本 次发行总量的 51.96%；网上社会公众投资者实际认购数量为 3,745,280 张，即 374,528,000.00 元，占本次发行总量的 45.84%；中信证券包销可转换公司债券的 数量为 179,340 张，包销金额为 17,934,000.00 元，占 ...

| 证券代码：300078 | 证券简称：思创医惠 公告编号：2024-068 | | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | 更正后： 会议问题征集：投资者可于 2024 年 5 月 21 日前访问网址 https://eseb.cn /1dDtV8H2x0s 或使用微信扫描下方小程序码进行会前提问，公司将通过本次业 绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 除上述更正外，《关于举行 2023 年度网上业绩说明会的公告》其他内容没 有变化。本次更正事项不影响公司其他公告内容，公司董事会就上述更正事项给 投资者带来的不便深表歉意。公司将在今后的信息披露工作中加强学习，提高信 息披露质量。 特此公告。 思创医惠科技股份有限公司董事会 思创医惠科技股份有限公司 关于举行 2023 年度网上业绩说明会的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日在巨 潮资讯网（http://www.cninfo.com.cn）披露 ...

中证鹏元资信评估股份有限公司 中证鹏元公告【2024】197 号 中证鹏元关于关注思创医惠科技股份有限公司被出具保留 意见审计报告等事项的公告 （2）2020 年度思创医惠及子公司部分交易对手杭州易捷医疗器 械有限公司、杭州闻然信息技术有限公司等多家单位与思创医惠原大 股东杭州思创医惠集团有限公司及其关联方存在直接或间接的资金 往来，且杭州思创医惠集团有限公司存在占用上市公司资金的情况； 思创医惠及子公司以前年度以自有资金和募集资金向杭州易捷医疗 器械有限公司、杭州菲诗奥医疗科技有限公司等多家公司采购了被服 柜、睡眠仪及其他软硬件，其中部分交易方为关联方。截至 2023 年 末，思创医惠因上述交易等形成的资产账面原值 23,396.91 万元，累 计计提折旧和摊销 8,285.68 万元，因被服柜、睡眠仪等设备闲置累计 计提减值准备 11,161.53 万元，账面价值 3,949.70 万元。 由于未能对上述事项实施必要的审计程序以获取充分、适当的审 计证据，2022 年度，审计机构对上述事项发表了保留意见。2023 年 度，审计机构仍然无法判断上述事项相关交易的商业实质及其真实 性、公允性、合理性，以及上述 ...

| 证券代码：300078 | 证券简称：思创医惠 公告编号：2024-065 | | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | 思创医惠科技股份有限公司 第五届董事会第四十一次会议决议公告 表决结果：7 票同意，0 票反对，0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn） 的《关于不向下修正"思创转债"转股价格的公告》（公告编号：2024- 066）。 2、审议通过了《关于投资设立全资孙公司的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 思创医惠科技股份有限公司（以下简称"公司"）第五届董事会第四十一 次会议于 2024 年 5 月 6 日以通讯方式召开。会议通知于 2024 年 5 月 6 日通过 电子邮件、电话方式送达各位董事，经全体董事一致同意，本次会议豁免通知 期限要求。本次会议应出席董事 7 人，实际出席董事 7 人。会议由董事长朱以 明先生召集并主持，公司监事和高级管理人员列席了会议。本次会议召集、召 开和表决程序符合《公 ...

2、2024 年 5 月 6 日，公司召开第五届董事会第四十一次会议，审议通过 了《关于不向下修正"思创转债"转股价格的议案》，公司董事会决定本次不 向下修正"思创转债"转股价格，同时在未来一个月内（即 2024 年 5 月 7 日至 2024 年 6 月 6 日），如再次触发"思创转债"转股价格向下修正条款，亦不提 出向下修正方案。下一触发转股价格修正条件的期间从 2024 年 6 月 7 日重新起 算，若再次触发"思创转债"转股价格的向下修正条款，届时公司董事会将再 次召开会议决定是否行使"思创转债"转股价格的向下修正权利。 一、可转换公司债券发行上市情况 | 证券代码：300078 | 证券简称：思创医惠 公告编号：2024-066 | | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | 思创医惠科技股份有限公司 关于不向下修正"思创转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、自 2024 年 4 月 10 日至 2024 年 5 月 6 日，思创医惠科技股份有限公司 （以下简称" ...

思创医惠科技股份有限公司 关于投资设立全资孙公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 | 证券代码：300078 | 证券简称：思创医惠 公告编号：2024-067 | | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | 销售；通信设备制造；通信设备销售；技术服务、技术开发、技术咨询、技术 交流、技术转让、技术推广；电子产品销售；机械设备租赁；技术进出口；货 物进出口；进出口代理（除依法须经批准的项目外，凭营业执照依法自主开展 经营活动） 1、根据公司业务规模发展及运营的需要，思创医惠科技股份有限公司（以 下简称"公司"）通过全资子公司杭州思创汇联科技有限公司（以下简称"思 创汇联"）拟在浙江省温州市苍南县投资设立全资孙公司思创物联（苍南）科 技有限公司（暂定名，最终以市场监督管理部门核准登记的名称为准），注册 资本为人民币 3,000.00 万元，拟使用自有资金认缴出资，思创汇联持股比例为 100%。 2、公司于 2024 年 5 月 6 日召开第五届董事会第四十一次会议，以 7 票同 意， ...

Financial Performance - The company's operating revenue for 2019 was CNY 1,539,064,250.50, representing an increase of 18.88% compared to CNY 1,294,633,555.55 in 2018[18]. - The net profit attributable to shareholders decreased by 20.48% to CNY 114,086,372.61 from CNY 143,472,605.91 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 86,207,291.39, down 33.93% from CNY 130,481,298.93 in 2018[18]. - The net cash flow from operating activities improved significantly to CNY 4,016,052.21, a 278.45% increase from a negative CNY 2,250,476.51 in 2018[18]. - Total assets increased by 22.45% to CNY 4,192,899,452.06 at the end of 2019, compared to CNY 3,424,095,703.68 at the end of 2018[18]. - The net assets attributable to shareholders rose by 30.41% to CNY 2,858,405,050.70 from CNY 2,191,940,887.06 in 2018[18]. - The company reported a basic earnings per share of CNY 0.14, down 22.22% from CNY 0.18 in 2018[18]. - The company achieved operating revenue of 1,539.06 million yuan, an increase of 18.88% compared to the previous year[53]. - Operating profit was 131.35 million yuan, a decrease of 19.38% year-on-year[53]. - Net profit attributable to shareholders was 114.09 million yuan, down 20.48% from the previous year[53]. - Basic earnings per share were 0.14 yuan[53]. Research and Development - The company's R&D investment totaled 161.20 million yuan, accounting for 10.47% of operating revenue, indicating a continuous focus on innovation in smart medical and commercial intelligence sectors[43]. - The company focused on R&D in key technologies such as artificial intelligence and IoT, enhancing its smart healthcare service ecosystem[54]. - The company invested CNY 138.08 million in R&D, accounting for 8.97% of its revenue, indicating a continuous enhancement of its core competitiveness[58]. - Research and development (R&D) investment amounted to 161.20 million yuan in 2019, representing 10.47% of total revenue, an increase from 9.25% in 2018[95]. - The number of R&D personnel increased to 1,176 in 2019, accounting for 52.36% of the total workforce, up from 38.47% in 2018[95]. - The company continues to invest in the independent research and development of artificial intelligence technology, solidifying its leading position in the medical AI field[45]. - The company has obtained multiple software copyrights for various healthcare platforms, including the "Medical Education Platform Software V1.0" and "Wound Specialty Nursing System Software V1.0" in 2019[48]. - The focus on software innovation is expected to drive future growth, with an emphasis on improving healthcare delivery and patient management systems[48]. Market Strategy and Expansion - The company aims to become a leading provider of smart medical and IoT application solutions, leveraging five core technologies including IoT and AI[27]. - The company is committed to expanding its market presence and enhancing its product offerings in the IoT sector[11]. - The company aims to enhance healthcare resource allocation efficiency and improve grassroots medical service capabilities through its integrated medical community solutions[31]. - The company is actively developing new technologies, as evidenced by the registration of the "Smart Management System for Medical Supplies" and "Personnel Positioning System Software" in early 2019[48]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[164]. - A strategic acquisition of a local competitor is expected to enhance the company's product offerings and customer base, with an estimated cost of $50 million[165]. - The company aims to launch two new products in Q2 2020, which are anticipated to contribute an additional $10 million in revenue[166]. - The company plans to transition its business model from system sales to operational service, enhancing revenue stability and cash flow through ongoing service income[137]. Dividend Policy - The company plans to distribute a cash dividend of 0.18 RMB per 10 shares to all shareholders, based on a total of 869,411,466 shares[5]. - The proposed cash dividend for 2019 is CNY 0.18 per 10 shares, totaling CNY 15,649,406.39, which represents 13.72% of the net profit[158]. - The cash dividend for 2018 was CNY 0.18 per 10 shares, totaling CNY 14,541,936.01, which accounted for 10.14% of the net profit[157]. - The cash dividend for 2017 was also CNY 0.18 per 10 shares, totaling CNY 14,541,936.01, representing 11.16% of the net profit[157]. - The cumulative undistributed profits as of the end of 2019 are CNY 137,964,083.98 for the parent company[156]. - The company has consistently maintained a cash dividend of CNY 0.18 per 10 shares over the past three years[157]. - The total cash dividends distributed over the past three years are CNY 15,649,406.39 for 2019, CNY 14,541,936.01 for 2018, and CNY 14,541,936.01 for 2017[158]. - The company’s retained earnings at the end of 2019 indicate a strong financial position for future distributions[156]. Technological Advancements - The company has developed an integrated platform technology for EAS and RFID, covering various industries including supply chain management and digital retail, enhancing operational management for clients[45]. - The AI cognitive engine ThinkGo is at the core of the company's efforts to improve clinical diagnosis and treatment levels through deep learning[45]. - The company collaborates with Baidu to promote the deep integration of AI technology in medical applications[45]. - The company has developed innovative IoT-based medical traceability management products, which significantly reduce labor costs for hospitals and enhance operational efficiency[59]. - The AI-driven medical service platform, supported by the company's proprietary AI engine ThinkGo, has been recognized as a leading application in the field of medical artificial intelligence[60]. - The company launched an "Internet + Nursing Service" platform, which has been well-received in the industry and expanded its reach to key hospitals across six pilot provinces and cities[61]. - The company secured multiple significant projects in the smart hospital sector, with individual project values exceeding CNY 10 million, enhancing its market presence[64]. - The company completed major IT infrastructure projects for hospitals, including a comprehensive information system upgrade for Guangzhou Women and Children's Medical Center within 18 months[66]. Corporate Governance and Compliance - The company emphasizes the importance of risk management in its future development outlook, as detailed in the report[5]. - The report highlights the company's commitment to ensuring the accuracy and completeness of its financial statements, as stated by the management[4]. - The company has appointed a board secretary and a securities affairs representative for investor relations[15]. - The company has established a stock option and restricted stock incentive plan involving 66 core technical and business personnel to enhance talent retention and motivation[75]. - The company has implemented an ERP information system project, which was completed in half the standard time, improving internal management efficiency[72]. - The company’s internal control audit was conducted by Tianjian Accounting Firm, which issued an internal control assurance report[181]. - The company has no significant litigation or arbitration matters during the reporting period[183]. - The company has no penalties or rectification situations during the reporting period[184].

Financial Performance - The company's operating revenue for 2020 was ¥1,374,795,956, a decrease of 10.67% compared to ¥1,573,993,606 in 2019[17]. - The net profit attributable to shareholders was ¥15,111,013.86, representing a significant decline of 86.75% from ¥147,607,911.10 in the previous year[17]. - The net cash flow from operating activities was negative at ¥8,034,958.61, a decrease of 300.07% compared to ¥4,016,052.21 in 2019[17]. - The total assets at the end of 2020 increased by 10.91% to ¥4,650,364,987 from ¥4,224,616,751 in 2019[18]. - The total equity attributable to shareholders decreased by 1.25% to ¥2,822,606,785 from ¥2,891,926,589 in 2019[18]. - The company reported a basic earnings per share of ¥0.020, down 85.71% from ¥0.18 in 2019[17]. - In Q4 2020, the operating revenue was ¥407,763,482.04, with a net profit attributable to shareholders of -¥9,524,193.27[20]. - The company reported a strong focus on R&D, with new technologies developed in areas like patient management and clinical data analysis, indicating a commitment to innovation[43]. - The company achieved significant R&D results with costs significantly lower than industry peers, establishing a solid foundation for systematic single-disease AI operation services[52]. - The company reported a total expected daily related transactions of no more than RMB 54 million with several related parties for the year 2020[175]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.13 per 10 shares to all shareholders, based on a total of 869,411,466 shares[4]. - The total cash dividend distributed for the year 2020 was CNY 11,302,349.06, representing 74.80% of the net profit attributable to shareholders[145]. - The cash dividend per 10 shares was CNY 0.13 (including tax), based on a total share capital of 869,411,466 shares[143]. - The cash dividend amount for 2019 was CNY 15,649,406.39, which accounted for 13.72% of the net profit attributable to shareholders[145]. - The cash dividend amount for 2018 was CNY 14,541,936.01, representing 10.14% of the net profit attributable to shareholders[145]. - The company has maintained a consistent cash dividend policy, with no changes to the distribution ratio despite fluctuations in total share capital due to various corporate actions[142]. - The cash dividend for 2020 was 100% of the total profit distribution amount, indicating a complete payout of available profits[142]. - The company has not proposed any ordinary cash dividend distribution plan for the current reporting period despite having positive distributable profits[145]. Research and Development - The company's total R&D investment reached 208.82 million yuan, accounting for 15.19% of revenue, with a year-on-year growth of 29.54%[38]. - The company is focusing on developing an Industrial IoT platform to enhance service capabilities in the industrial manufacturing sector[79]. - The company is working on an intelligent medication dispenser using IoT and AI to improve medication adherence for elderly patients[81]. - The company achieved a 95% success rate in developing a knowledge graph-based clinical decision support system and medical research services, indicating significant advancements in precision medicine with broad market prospects[82]. - The company is developing an AI-based clinical decision support system with a 70% success rate, focusing on enhancing diagnostic capabilities for diseases such as lung cancer and coronary heart disease[83]. Market Expansion and Strategy - The company aims to expand its market presence both domestically and internationally, primarily targeting large and medium-sized hospitals and healthcare institutions[32]. - The company is actively pursuing partnerships and collaborations to enhance its product offerings and market reach, indicating a strategy for growth through alliances[43]. - The company is transitioning its smart medical business from a system sales model to an operational service model, aiming for stable service revenue[60]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its technological capabilities in the healthcare sector[43]. - The company is facing intensified competition in both the smart healthcare and commercial intelligence sectors, necessitating continuous innovation and market adaptation[127]. Risk Management - The company emphasizes the importance of risk management in its future development outlook, as detailed in the report[4]. - The company is actively managing accounts receivable risks, focusing on improving collection processes to reduce cash flow impacts from slow receivables[130]. - The company is committed to using appropriate currency management tools and insurance to mitigate risks from exchange rate fluctuations[130]. - The company acknowledges potential goodwill impairment risks from acquisitions, particularly if future performance does not meet expectations[132]. - The company is aware of the impact of the COVID-19 pandemic on its business operations, particularly in export sales and timely collections[130]. Corporate Governance - The report confirms that all board members attended the meeting to review the annual report, ensuring governance and accountability[4]. - The company is focusing on improving its internal control systems and governance structure to enhance operational efficiency and risk management[65]. - The company has committed part of the raised funds to be invested in planned projects, with some funds temporarily used for liquidity and structured deposits[105]. - The company has not experienced any major changes in the measurement attributes of its main assets during the reporting period[96]. - The company has no significant related party transactions during the reporting period[171]. Technology and Innovation - The company aims to build a "smart medical ecosystem" through its E-SMART 3.0 solution, enhancing user experience and addressing issues of fragmented medical data[38]. - The company launched the E-SMART 3.0 smart medical cloud ecosystem service system, enhancing hospital information design and solution delivery capabilities[54]. - The company is leveraging its experience in non-core medical operations to expand into core medical operational services, aiming to improve revenue structure and profitability[60]. - The company is recognized as one of the largest RFID technology research and production bases globally, with stable partnerships with over 300 clients and agents[119]. - The company has developed and passed several international standards in healthcare information technology, marking a breakthrough for China in this field[116].